Lipocine (LPCN) Price & Analysis

Compare

911 Followers

LPCN Stock Chart & Stats

$2.92

-$0.05(-1.04%)

At close: Jan 08 4:00 PM EST

$2.92

-$0.05(-1.04%)

Day’s Range― - ―

52-Week Range$2.52 - $5.50

Previous CloseN/A

Volume16.76K

Average Volume (3M)69.37K

Market Cap

$23.60M

Enterprise Value$296.40K

Total Cash (Recent Filing)$15.13M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.87

Next Earnings

Mar 05, 2026

EPS Estimate

-0.61

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.59

Shares Outstanding5,551,931

10 Day Avg. Volume103,401

30 Day Avg. Volume69,372

Financial Highlights & Ratios

PEG Ratio-31.18

Price to Book (P/B)1.24

Price to Sales (P/S)2.33

P/FCF Ratio-19.87

Enterprise Value/Market Cap0.01

Enterprise Value/Revenue0.07

Enterprise Value/Gross Profit0.14

Enterprise Value/Ebitda-0.05

Forecast

1Y Price Target

$6.88

Price Target Upside135.62% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-1.92

Revenue Forecast (FY)$940.00K

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentThe Phase 3 trial of LPCN 1154 in postpartum depression is on track to report topline data, which could lead to a new drug application submission in the U.S.

Efficacy And SafetyLipocine's LPCN 1154 improves the efficacy and safety profile compared to other treatments, with a rapid onset of action and no adverse events in trials.

Market PotentialLPCN 1154 has the potential to become the best-in-class neuroactive steroid that could satisfy unmet needs in postpartum depression.

Bears Say

Financial NeedsThe company may choose to raise additional capital within the next 12 months, indicating potential financial needs.

Financial PerformanceNet loss was $2.2M, or ($0.41) per share, in line with the estimated loss.

Lipocine News

Lipocine ‘s PPD Phase 3 study hits 80% enrollment milestone

Lipocine (LPCN) announced 80% completion of enrollment in the ongoing Phase 3 clinical trial evaluating LPCN 1154, or...

7d ago

LPCN

Lipocine Advances Phase 3 Trial for PPD Treatment

Lipocine ( ($LPCN) ) has shared an announcement. On December 16, 2025, Lipocine announced that its Phase 3...

7d ago

LPCN

Lipocine Showcases LPCN 2101 at Epilepsy Meeting

An update from Lipocine ( ($LPCN) ) is now available. Lipocine presented posters for LPCN 2101 at the...

11d ago

LPCN

Lipocine Announces Positive Interim Results for PPD Trial

Lipocine ( ($LPCN) ) has shared an update. On November 18, 2025, Lipocine announced promising interim safety results...

1M ago

LPCN

Lipocine Updates Corporate Presentation for Investors

Lipocine ( ($LPCN) ) just unveiled an update. Lipocine has updated its corporate presentation, which is used for...

1M ago

LPCN

Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154

Lipocine (LPCN) announced the completion of a scheduled independent Data Safety Monitoring Board review of its ongoing Phase...

1M ago

LPCN

Lipocine price target lowered to $7 from $8 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Lipocine (LPCN) to $7 from $8 and keeps a Buy...

1M ago

LPCN

Lipocine Inc. Reports Q3 2025 Financial Results

Lipocine Inc ( ($LPCN) ) has released its Q3 earnings. Here is a breakdown of the information Lipocine...

2M ago

LPCN

Lipocine reports Q3 EPS (59c) vs. (44c) last year

Reports Q3 revenue $114.57M vs. $0 last year. As of September 30, 2025, Lipocine (LPCN) had $15.1M of...

2M ago

LPCN

Lipocine Presents Promising LPCN 2401 Data at ObesityWeek

An announcement from Lipocine ( ($LPCN) ) is now available. On November 4, 2025, Lipocine Inc. presented clinical...

2M ago

LPCN

Lipocine Inc (LPCN) Q3 Earnings Cheat Sheet

Lipocine Inc (LPCN) is scheduled to report 3rd quarter earnings on 11/05/2025. Regarding Q3 estimates, Wall Street analysts...

2M ago

LPCN

Lipocine Advances Phase 3 Trial for PPD Treatment

Lipocine ( ($LPCN) ) has provided an update. Lipocine Inc. announced progress in its Phase 3 clinical trial...

3M ago

LPCN

Lipocine provides update on Phase 3 clinical trial in postpartum depression

Lipocine (LPCN) provided an update on its ongoing pivotal Phase 3 clinical trial evaluating LPCN 1154 for the...

3M ago

LPCN

Lipocine Seeks Regulatory Clarity on LPCN 2401 Study

Lipocine ( ($LPCN) ) just unveiled an announcement. Lipocine has updated its corporate presentation, reflecting its focus on...

3M ago

LPCN

LPCN FAQ

What was Lipocine Inc’s price range in the past 12 months?

Lipocine Inc lowest stock price was $2.52 and its highest was $5.50 in the past 12 months.

What is Lipocine Inc’s market cap?

Lipocine Inc’s market cap is $23.60M.

When is Lipocine Inc’s upcoming earnings report date?

Lipocine Inc’s upcoming earnings report date is Mar 05, 2026 which is in 72 days.

How were Lipocine Inc’s earnings last quarter?

Lipocine Inc released its earnings results on Nov 06, 2025. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.54 by -$0.05.

Is Lipocine Inc overvalued?

According to Wall Street analysts Lipocine Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Lipocine Inc pay dividends?

Lipocine Inc does not currently pay dividends.

What is Lipocine Inc’s EPS estimate?

Lipocine Inc’s EPS estimate is -0.61.

How many shares outstanding does Lipocine Inc have?

Lipocine Inc has 5,551,931 shares outstanding.

What happened to Lipocine Inc’s price movement after its last earnings report?

Lipocine Inc reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.54. Following the earnings report the stock price went up 3.125%.

Which hedge fund is a major shareholder of Lipocine Inc?

Currently, no hedge funds are holding shares in LPCN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lipocine Inc

Lipocine Inc. (LPCN) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics based on its proprietary drug delivery technology. The company primarily operates in the healthcare sector, specializing in the treatment of metabolic and endocrine disorders, including testosterone deficiency and liver disease. Lipocine's core products include LPCN 1144, an oral testosterone replacement therapy, and LPCN 1107, a treatment for nonalcoholic steatohepatitis (NASH), which leverage its unique lipid-based delivery system to enhance bioavailability and patient compliance.

Lipocine (LPCN) Earnings & Revenues

Historic Earnings Reports

LPCN Stock 12 Month Forecast

Average Price Target

$6.88

▲(135.62% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","8":"$8","2.75":"$2.75","4.5":"$4.5","6.25":"$6.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.75,4.5,6.25,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.66,2.993846153846154,3.327692307692308,3.661538461538462,3.9953846153846158,4.32923076923077,4.663076923076924,4.996923076923077,5.330769230769231,5.664615384615384,5.998461538461539,6.332307692307692,6.666153846153846,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.66,2.9846153846153847,3.309230769230769,3.6338461538461537,3.9584615384615383,4.283076923076923,4.607692307692307,4.932307692307692,5.256923076923076,5.581538461538461,5.906153846153845,6.23076923076923,6.555384615384615,{"y":6.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.66,2.974615384615385,3.2892307692307696,3.603846153846154,3.9184615384615387,4.233076923076924,4.547692307692308,4.862307692307692,5.176923076923077,5.491538461538462,5.806153846153847,6.1207692307692305,6.435384615384615,{"y":6.75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.56,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.67,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >